ILC - 2019 - конференция EASL

[Nessi]

10-14 апреля 2019 года в Вене будет проходить очередная конференция EASL - ILC 2019.

Размещаю ссылку на сборник абстрактов для ознакомления:
https://ilc-congress.eu/wp-content/uplo ... 032019.pdf

[igrikk]

Хорошо бы такой журнальчик нс русском

[Nessi]

[Nessi]

[Люлек]

Nessi, пожалуйста объясните!?очень интересно !

[Nessi]

Люлек,
я очень надеюсь, что это сделают другие, я крайне занята
пока размещаю, что показалось наиболее интересным

[Nessi]

Patients with non-characterized nodules before DAA treatment have 3 times higher risk of HCC development than patients without and with a clear time association.
Clear-cut time association between DAA treatment and hepatocellularcarcinoma incidence.

Извиняюсь за большую картинку.

Вот по этому нужно искать подробности, звучит устрашающе.

[Люлек]

Nessi, спасибо большое !!!

[Nessi]

Interesting data on persistence of RAS post DAA failure. Ns3 RAS decrease over time, bar q80k in GT1a, as expected. Surprising that NS5a RAS seem to fall in GT1a, particularly Y93H.

[Nessi]

It seems that myrcludexB + PegIFN works in HepatitisD, but is also effective suppressing HepatitisB in these co-infected patients. We are closer to find a cure.

[Nessi]

Analysis of hepatitisCvirus subtypes from 91 African immigrants treated at one London center showed 35 were infected by novel G1 subtypes (15 found), and sustained virologic response to direct-acting antivirals was just 75% in these pts. Finding suggests that African residents may harbor several as-yet poorly studied HCV subtypes that are not fully responsive to current HCV antivirals and that new agents may be needed for global HCV control.

[Nessi]

24weeks of sofosbuvir only (no RBV) for chronic HEV with failure of/contraindication to full dose RBV. Early Virological response in 8/9, but not sustained. No patients became negative. Dissapointing but perhaps not surprising. Sofosbuvir shows moderate antiviral efficacy but does not lead to cure of chronic hepatitisE. Sofosbuvir shouldn't be used as monotherapy for chronic hepatitis E but may be further investigated in combination with ribavirin.

[Nessi]

Hep B project, interim analysis, only a quarter have reached 24 weeks, safety looking good.

[Nessi]

ASMB showing “never been shown before” DNA declines to below detectable in nuc suppressed hep B patients. Antigen declines expected to follow...

[Nessi]

ASMB showing “never been shown before” DNA declines to below detectable in nuc suppressed hep B patients. Antigen declines expected to follow...